Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 03, 2022 12:50 ET | Source: Oxeia Biopharmaceuticals Inc.

OXEIA ANNOUNCES POSITIVE INTERIM RESULTS OF PHASE 2 TRIAL FOR OXE103 FOR THE TREATMENT OF CONCUSSIONS

Phase 2 clinical trial for OXE103 for the treatment of concussion is being conducted at University of Kansas Medical Center, Kansas City, KansasEnrolling highly symptomatic participants within 28 days...